title: Models for narcolepsy with cataplexy drug discovery.
abstract: BACKGROUND
  Narcolepsy is a chronic sleep disorder, characterized by a disrupted nocturnal sleep, excessive daytime sleepiness (EDS) and symptoms of dissociated rapid eye movement (REM) sleep. These symptoms are often disabling, confining the patients to a life-long pharmacologic symptomatic treatment. Nowadays, it is well known that narcolepsy results from alterations in the genes involved in the physiology of the orexin ligand or its receptor.
  
  
  METHODS
  This review recapitulates on the current approaches for treating narcolepsy with cataplexy and the use of narcolepsy models in order to address different aspects of the disease.
  
  
  CONCLUSIONS
  Animal models are required for the study of human diseases when it is impractical or unethical to use humans; these models are useful for studying the underlying causes of a disease and are a common research tool for identifying potential drug targets. Current treatment for human narcolepsy is symptomatically based; interestingly, the existing approaches do not target the orexinergic circuit. The discovery of novel drug targets for treating narcolepsy remains the primary focus of study in sleep medicine research. New therapies will arise through the discovery of new animal models of narcolepsy, which will offer new insights into the understanding of its physiopathology.
authors.affiliation: Departamento de Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México.
authors.forename: Alberto K
authors.initials: AK
authors.lastname: De la Herrán-Arita
authors.forename: René
authors.initials: R
authors.lastname: Drucker-Colín
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000008:administration & dosage / Q000378:metabolism; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D009290:Narcolepsy / Q000188:drug therapy* / Q000503:physiopathology; D009479:Neuropeptides / Q000008:administration & dosage / Q000378:metabolism; D064446:Orexin Receptors; D000068797:Orexins; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism; D018013:Receptors, Neuropeptide / Q000378:metabolism
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D064446:Orexin Receptors; D000068797:Orexins; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide